ArticleFood science & nutrition2025
Erchen Decoction Offers Health Benefits in Regulating Obesity: Component Analysis, Network Pharmacology, and Experiment Verification.
Article in Food science & nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Erchen Decoction Offers Health Benefits in Regulating Obesity: Component Analysis, Network Pharmacology, and Experiment Verification.Food science & nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erchen Decoction (ECT) is composed of six plants and fruits, with potential for treating metabolic diseases. However, its regulatory effects and material basis on simple obesity have not been reported. In this study, we predicted potential targets and pathways of ECT intervention on simple obesity through component analysis and network pharmacology. Subsequently, the predicted targets and regulatory pathways were validated via animal experiments. A total of 93 compounds were identified in ECT and 221 overlapping potential targets were identified between ECT and obesity. KEGG enrichment analysis revealed that the regulatory pathways of ECT may involve lipid metabolism, oxidative stress regulation, and immune modulation. Molecular docking experiments demonstrated that the main components of ECT, including Sachaliside, Naringenin, Liquiritigenin, maclurin, and Rhapontigenin, exhibited strong binding affinities with oxidative stress and immune markers. Animal experiments demonstrated that ECT has significant potential for weight loss and lipid-lowering effects, especially mitigating hepatic oxidative stress and systemic inflammation through the LPS-TLR4/MyD88/NF-κB signaling pathway. This study provides fundamental data for the further development of ECT as a potential functional food for regulating simple obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.